5 j a n u a r y 2 0 1 7 | V O L 5 4 1 | n a T u r E | 8 1 LETTEr a list of authors and affiliations appears at the end of the paper. Approximately 1.5 billion people worldwide are overweight or affected by obesity, and are at risk of developing type 2 diabetes, cardiovascular disease and related metabolic and inflammatory disturbances 1,2 . Although the mechanisms linking adiposity to associated clinical conditions are poorly understood, recent studies suggest that adiposity may influence DNA methylation 3-6 , a key regulator of gene expression and molecular phenotype 7 . Here we use epigenome-wide association to show that body mass index (BMI; a key measure of adiposity) is associated with widespread changes in DNA methylation (187 genetic loci with P < 1 × 10 −7 , range P = 9.2 × 10 −8 to 6.0 × 10 −46 ; n = 10,261 samples). Genetic association analyses demonstrate that the alterations in DNA methylation are predominantly the consequence of adiposity, rather than the cause. We find that methylation loci are enriched for functional genomic features in multiple tissues (P < 0.05), and show that sentinel methylation markers identify gene expression signatures at 38 loci (P < 9.0 × 10 −6 , range P = 5.5 × 10 −6 to 6.1 × 10 −35 , n = 1,785 samples). The methylation loci identify genes involved in lipid and lipoprotein metabolism, substrate transport and inflammatory pathways. Finally, we show that the disturbances in DNA methylation predict future development of type 2 diabetes (relative risk per 1 standard deviation increase in methylation risk score: 2.3 (2.07-2.56); P = 1.1 × 10 −54 ). Our results provide new insights into the biologic pathways influenced by adiposity, and may enable development of new strategies for prediction and prevention of type 2 diabetes and other adverse clinical consequences of obesity.
little evidence for heterogeneity between Europeans and Indian Asians (Supplementary Table 3 ). At seven loci, the associations between DNA methylation and BMI are stronger amongst Indian Asians or Europeans (heterogeneity P < 1.0 × 10 −7 ), raising the possibility that some effects may be population specific.
Sensitivity analyses show that our findings are robust to the choice of analytic strategy. The associations of DNA methylation in blood with BMI are not explained by population stratification caused by DNA sequence variation, or by genetic confounding of single-nucleotide polymorphisms (SNPs) in the probe sequence (Supplementary Table 5 and Supplementary Figs 3, 4 ). In addition, to address the possibility of confounding by technical factors, we further replicated the associations of DNA methylation in blood with BMI at 4 loci, in 990 Europeans and 1,720 Indian Asians (LOLIPOP study), using pyrosequencing as an alternative approach to quantification of methylation (P = 1.2 × 10 −7 to 2.1 × 10 −12 for association of methylation with BMI; Supplementary  Table 6 ).
The 187 identified methylation markers are strongly enriched for CpG sites with intermediate levels of methylation, consistent with the presence of mosaicism, that is, epigenetic heterogeneity, at these loci (P = 1.4 × 10 −22 , Fisher's test; Extended Data Fig. 2 ). To better understand the underlying cellular events, and exclude changes in cell subset composition as the basis for our findings, we carried out replication testing of the sentinel loci in isolated white-blood-cell subsets (monocytes, neutrophils, CD4 + T cells and CD8 + T cells, n = 60; Supplementary Table 7 ). Epigenetic heterogeneity is present at the majority of loci, in each of the cell subsets studied (Extended Data Fig. 3 and Supplementary Table 8 ). The sentinel markers are enriched for association with adiposity in each of the isolated cell subsets (Extended Data Fig. 4 and Supplementary Table 8 ), and the relationships between methylation and obesity are directionally consistent with the discovery epigenome-wide association study at 130 loci (CD4 + , P = 1.2 × 10 −9 , sign test) and 166 loci (neutrophils, P = 5.6 × 10 −35 , sign test) ( Supplementary Table 9 ). Furthermore, effect sizes are directionally consistent and of similar magnitude between the isolated cell subsets (Extended Data Fig. 5 ). The association of DNA methylation with BMI therefore reflects epigenetic heterogeneity at the identified loci, is independent of changes in cell subset distribution, and comprises an effect of adiposity on methylation that is shared across the cell subsets studied.
To assess the relevance of our observations in blood to other metabolically relevant tissues, we first compared methylation levels at the 187 loci in blood, subcutaneous and omental fat, liver, muscle, spleen and pancreas 9 . Mean methylation levels at the 187 loci correlate moderately to strongly between the tissues (R = 0.37− 0.93, P = 8.9 × 10 −8 to 1.9 × 10 −82 for the 21 tissue pairs; Extended Data Fig. 6 and Supplementary Fig. 5 ), supporting the view that methylation levels in blood are related to methylation patterns in other tissues at the CpG sites examined.
Inflammatory and hormonal disturbances in adipocytes of obese people contribute to the development of insulin resistance and other metabolic consequences of adiposity 10 . To better understand how our findings in the blood might reflect processes in the adipose tissue,
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we therefore quantified the relationship between DNA methylation and BMI in adipose tissue. We found that 120 of the CpG sites show directional consistency for association with BMI in both adipose tissue and blood (P = 1.3 × 10 −4 , binomial test), whereas 91 sites are associated with BMI in adipose tissue (P < 2.7 × 10 −4 , that is, P < 0.05 after Bonferroni correction for 187 tests; Supplementary Table 10 ). The associations of DNA methylation with BMI in adipose tissue are also unlikely to be the result of differences in the composition of canonical cell types. First we used principal component analysis to assess the cryptic structure arising from variation in cell subset composition in the methylation data. Including principal components as covariates in regression models did not materially influence the association of DNA methylation with BMI in adipose tissue ( Supplementary Fig. 6 ). In separate studies, we quantified DNA methylation in isolated adipocytes from subcutaneous adipose tissue collected from morbidly obese (BMI > 40 kg m −2 , n = 24) and normal weight (n = 24) individuals. Despite the small sample size, 6 out of 187 sentinel markers were associated with obesity at P < 2.7 × 10 −4 (P < 0.05 after Bonferroni correction; Supplementary Table 11 ), and 108 markers show relationships with obesity that are directionally consistent with those observed in the discovery epigenome-wide association study (P = 0.04). We separately tested the association of our sentinel methylation markers with BMI in samples of the liver (n = 55), as this is also a metabolically relevant tissue. We found that 114 CpG sites showed consistent direction of association with BMI compared to our findings in blood (P = 0.001, sign test; Supplementary Table 10 ). Our findings indicate that many of the relationships between methylation and BMI in blood are shared by adipose and liver cells, but also identify effects that are tissue specific.
Next, we used genetic association and the concept of Mendelian randomization to investigate the potential causal relationships between DNA methylation in blood and BMI 11 . We first identified SNPs influencing DNA methylation in blood in cis (1 Mb, n = 4,034 people). We then tested whether SNPs that influence methylation in blood also influence BMI, and whether the predicted effects of SNPs on BMI through methylation are consistent with the observed association. We identified a single CpG (cg26663590: NFATC2IP) that showed evidence of a genetic association for a causal role of methylation on BMI (P = 9.6 × 10 −7 for association of SNP rs11150675 near NFATC2IP with BMI; Fig. 2a and Supplementary Table 12 ). In keeping with a causal role for methylation at NFATC2IP underlying adiposity, baseline levels of methylation at cg26663590 predict weight gain in longitudinal population studies (P = 0.03, Supplementary Table 13 ). The NFATC2IP locus contains the gene that encodes SH2B1, which is known to be involved in energy and glucose homeostasis and has previously been linked with obesity, including in genome-wide association studies 12, 13 .
To investigate whether DNA methylation in blood is the consequence of adiposity, we used a weighted genetic risk score that combines effects across SNPs known to influence BMI ( Fig. 2b and Supplementary Table 14 ). We observed a strong correlation between predicted (through BMI) and observed effects of BMI genetic risk score on methylation (R 2 = 0.65; P = 4.7 × 10 −44 ) at the CpG sites evaluated. In particular, genetic risk score was associated with DNA methylation at the ABCG1, KLHL18 and FTH1P20 loci with P < 2.7 × 10 −4 (corresponding to P < 0.05 after Bonferroni correction for 187 tests). An effect of BMI on ABCG1 methylation is consistent with observations that weight loss influences both ABCG1 expression in adipose tissue and ABCG1 
DH CR 24 Results are presented as CpG-specific association test results (− log 10 (P)) ordered by genomic position. Green and blue symbols, CpG sites at loci reaching epigenome-wide significance (P < 1 × 10 −7 ); grey symbols, CpG sites at loci not reaching epigenome-wide significance. Chromosome numbers are shown on the inner ring. Tick marks on the outer ring identify the genomic loci reaching epigenome-wide significance. The genes nearest to the sentinel methylation markers at each of the 187 loci are listed around the circos plot.
activity 14, 15 , and by the close relationship between change in BMI and change in methylation during longitudinal follow-up analyses of participants in our population studies ( Fig. 3 and Supplementary  Table 13 ). Although further studies are needed to consider mechanisms, our findings suggest that adiposity determines the alterations in methylation at the majority of the identified CpG sites. We used genetic association separately to test the causal relationships between BMI and DNA methylation in adipose tissue. The results further confirm that in adipose tissue, as in blood, the differences in methylation observed are primarily the consequence of adiposity (R = 0.73, P = 1.6 × 10 −32 ; Extended Data Fig. 7 ).
We carried out functional genomic analyses to investigate the potential mechanisms linking the 187 sentinel CpGs sites with adiposity. The CpG sites are strongly enriched in active chromatin sites, including at DNase hypersensitivity sites and the activating histone marks H3K4me1 and H3K27ac in a wide range of cell lines (P < 0.05; Supplementary Fig. 7 ), suggesting that the adiposity-related methylation changes we identified occur at constitutive cis-regulatory regions that operate across tissues. In keeping with a regulatory role, DNA methylation at the 187 CpG sites is enriched for association with expression of cis genes (500 kb) in blood (Supplementary Tables 15,  16 and Extended Data Fig. 8 ). We find 44 transcripts of 38 annotated genes that are associated with DNA methylation at P < 9.0 × 10 −6 (that is, P < 0.05 after Bonferroni correction; Supplementary Table 16 ); an approximate threefold enrichment compared to expectations under the null hypothesis (P = 3.0 × 10 −4 ; Extended Data Fig. 8 ). Sensitivity analyses, by limiting assessment of the relationship between methylation and gene expression to the nearest gene or Illumina-annotated gene, identified five additional loci potentially associated with gene expression (Supplementary Table 17 ). The strongest cis signals observed were for cg09315878 with TNFRSF4 transcription (P = 7.2 × 10 −86 ), cg14476101 with PHGDH transcription (P = 1.0 × 10 −64 ) and cg09152259 with MAP3K2 transcription (P = 1.6 × 10 −67 ). On average, a 5% absolute change in methylation was associated with a 7% change in gene expression across the 44 transcripts identified (range 1.8% for AKAP to 19% for SPNS3; Supplementary Table 16 ). Among the 38 methylation-gene expression associations observed in blood, 3 were also found in adipose tissue (HOXA5, BBS2 and SELM (also known as SELENOM) and 3 in the liver (ANXA1, LGALS3BP and PHGDH) at P < 1.3 × 10 −3 (that is, P < 0.05 after Bonferroni correction for 38 tests), all with consistent direction of effect (Supplementary Table 18 ), suggesting that the relationships between methylation and Predicted effect Predicted effect Figure 2 | Genetic association studies to investigate the potential relationships between BMI and DNA methylation in blood. a, Results for the causality analysis investigating whether DNA methylation in blood at the sentinel CpG sites influences BMI. Units are change in BMI per copy of effect allele. For each sentinel CpG site, we identified the cis SNP (1 Mb) most closely associated with DNA methylation levels. For each SNP, we then determined the effect of SNP on BMI predicted via methylation (x axis) and the directly observed effect of the SNP on BMI (y axis). Grey, CpGs not significantly associated with a SNP; blue, CpGs significantly associated with a SNP. For a single CpG (NFATC2IP) the associated SNP is also associated with BMI and 95% CI error bars are shown. At the other loci, there was little relationship between the effects of the SNPs on BMI predicted through methylation and directly observed BMI (R 2 = 0.00, P = 0.86). b, Consequential analysis for a causality analysis investigating whether DNA methylation in blood at the sentinel CpG sites is the consequence of BMI. Units are change in methylation per unit change in weighted genetic risk score. We identified the SNPs reported to influence BMI in a genome-wide association meta-analysis 12 , and calculated a weighted genetic risk score (see Methods). For each sentinel CpG site, we then determined the effect of genetic risk score on methylation predicted through BMI (x axis) and the directly observed effect of genetic risk score on CpG (y axis). Three CpGs (ABCG1, KLHL18 and FTH1P20) are associated with the genetic risk score at P < 2.7 × 10 −4 (P < 0.05 after Bonferroni correction for 187 tests; 95% CI error bars shown). The overall correlation between observed and predicted effects (R 2 = 0.81; P = 4.7 × 10 −44 ) suggests that methylation in blood at the majority of CpG sites is consequential to BMI. Letter reSeArCH gene expression are in part shared between blood, adipose and liver tissue.
We prioritized genes as potential candidate genes involved in the association between BMI and DNA methylation at the 187 loci on the basis of two criteria: (1) proximity, the gene nearest to the sentinel methylation marker and (2) functional genomics, genes within 500 kb of the sentinel methylation marker showing association of gene expression with methylation ( Supplementary Table 19 ). These criteria identified 210 unique genes, many with established roles in adipose tissue biology and insulin resistance (for example, ABCG1, LPIN1, HOXA5, LMNA, CPT1A, SOCS3, SREBF1 and PHGDH; Supplementary Tables 19, 20) . Gene-set enrichment analyses show that the 210 candidate genes are enriched for genes involved in lipid and lipoprotein metabolism, amino-acid and small-molecule transport, and inflammatory pathways involving NF-κ B, MAPK, TAK1 (also known as MAP3K7), IRAK2 and TRAF6 (Supplementary Table 21 ).
To investigate the potential clinical significance of the DNA methylation changes, we first tested the cross-sectional relationship of DNA methylation in blood with fasting glucose, insulin, HDL (high-density lipoprotein) cholesterol, triglycerides, Haemoglobin A1c (HbA1c) and other clinical traits. We found that 879 methylationclinical-trait pairs tested were significant at P < 2.1 × 10 −5 (that is, P < 0.05 after Bonferroni correction for the 2,431 tests performed; Supplementary Fig. 8 and Supplementary Table 22 ), consistent with recent studies reporting close relationships of DNA methylation with blood lipids and glucose traits 16, 17 . We used genetic association to investigate the potential causal relationships between DNA methylation and the identified clinical traits. SNPs influencing methylation markers in blood showed little evidence for association with the respective clinical traits (Extended Data Fig. 9 ). By contrast, the predicted effect of genetic risk score on DNA methylation through clinical trait is correlated with the directly observed effect of genetic risk score on methylation for HbA1c, HDL cholesterol, triglycerides and insulin (P = 1 × 10 −3 to 2 × 10 −14 ; Extended Data Fig. 9 ). Our findings suggest that the methylation changes in blood may in part be a consequence of the changes in lipid and glucose metabolism associated with BMI.
Finally, we tested whether DNA methylation levels in blood at the 187 sentinel CpG sites predict new onset, incident type 2 diabetes, a major clinical consequence associated with obesity, in parti cipants of the LOLIPOP study (n = 2,664). In single-marker tests, 62 of the 187 methylation markers were associated with incident type 2 diabetes at P < 2.7 × 10 −4 (that is, P < 0.05 after Bonferroni correction; Supplementary Table 23 ). The strongest association was observed for the ABCG1 locus, a gene known to be involved in insulin secretion and pancreatic β -cell function 14, 15 . To integrate information across CpG sites, we calculated a weighted methylation risk score as the sum of methylation values at each of the markers associated with type 2 diabetes, weighted by marker-specific effect size. Methylation risk score is strongly predictive of incident type 2 diabetes (relative risk 2.29 (95% confidence intervals (CI), 2.06-2.55) per 1 s.d. change in methylation risk score; P = 4.2 × 10 −52 ). The association of methylation risk score with incident type 2 diabetes was also found in Europeans from the KORA study (relative risk, 2.51; (95% CI, 1.49-4.23) per 1 s.d. change in methylation risk score; P = 5.7 × 10 −4 ), with no evidence for heterogeneity of effect (P = 0.74). Methylation risk score predicts type 2 diabetes beyond traditional risk factors including BMI and waist-hip ratio ( Supplementary Table 24 ), and in particular identifies obese and overweight individuals with a high risk of developing type 2 diabetes in the future(relative risk for type 2 diabetes in obese subjects: 7.3 (4.1-12.9), P = 8.2 × 10 −12 in the top compared to the lowest quartile; Fig. 4 ). This risk of type 2 diabetes associated with DNA methylation markers, which we have estimated in our study is numerically similar to, or greater than, the estimated risk conferred by traditional risk factors, including overweight, obesity, central obesity, impaired fasting glucose and hyperinsulinaemia (Extended Data Fig. 10 ). Furthermore, DNA methylation remains strongly and independently associated with risk of future type 2 diabetes even after adjustment for adiposity and glycaemic measures. By contrast, emergent risk factors such as C-reactive protein and amino acid concentrations showed little evidence for an independent association with type 2 diabetes. Our findings therefore raise the possibility that DNA-methylation markers may help to identify individuals with metabolically unfavourable adiposity that are at increased risk of developing type 2 diabetes.
Our large-scale epigenome-wide association study identifies and replicates changes in DNA methylation associated with BMI in blood and adipose tissue. The associations of methylation with BMI are independent of variation in cell subset composition and replicate in both isolated white blood cells and isolated adipocytes. Genetic association in both blood and adipose tissue supports the view that the changes in DNA methylation are a consequence and not the cause of adiposity, at the majority of the identified CpG sites. The presence of epigenetic heterogeneity at the identified loci, even within isolated canonical cell subsets, together with a graded relationship between methylation and BMI, suggest epigenetic reprogramming within committed cell subsets in response to adiposity, as recently described in other tissues 18 . In keeping with this, the methylation loci are enriched for sites of open chromatin in multiple tissues, consistent with the presence of constitutive cis enhancers.
The candidate genes at these loci include genes with annotated roles in lipid metabolism, amino acid and small molecule transport, inflammation, as well as metabolic, cardiovascular, respiratory and neoplastic disease. For example, TNFRSF4 and MAP3K2 encode proteins involved in activation of NF-κ B 19 , whereas IL5RA is involved in development and activation of eosinophil and other immune cells, and is causally linked to asthma, eczema and cardiovascular disease 20 . ABCG1 is involved in cholesterol and phospholipid transport, and regulates insulin secretion 17, 21 . Our observations thus provide insight into the regulatory pathways that may link adiposity to metabolic and cardiovascular disease, asthma and a wide range of cancers, although our study is limited in the tissues examined, and further studies are needed to include additional biologically relevant tissues. Our prospective population studies show that DNA methylation identifies people at high risk of incident type 2 diabetes, independent of conventional risk factors. Further studies are needed to examine whether DNA-methylation markers may be useful in distinguishing metabolically unhealthy obesity. This may prove useful in risk stratification and personalized medicine, to help to tackle the current global epidemic of obesity and its associated cardiovascular and metabolic disturbances. 
Letter reSeArCH MethODS Population samples. Details of the population samples for discovery and replication are provided in the Supplementary Information. No statistical methods were used to predetermine sample size. The experiments were not randomized. All molecular assays were carried out blind to clinical status. Quantification of DNA methylation. DNA methylation was quantified in bisulfite-converted genomic DNA from whole blood, using the Illumina Infinium HumanMethylation450 array for all samples. Cohort specific methods are summarized in Supplementary Table 2 . DNA methylation was quantified on a scale of 0-1, in which 1 represents 100% methylation. Preprocessing and quality control criteria are summarized in Supplementary Table 2 .
The association of DNA methylation with BMI (a measure of adiposity) was tested in each cohort separately by linear regression using an established analytic strategy to reduce batch effects and other technical confounding effects in quantification of DNA methylation, and to take the potential confounding effects arising from cryptic alterations in the white blood cell composition of blood into account. In brief, in the LOLIPOP and KORA studies, raw signal intensities were retrieved using the function readIDAT of the R package minfi v.1.6.0 from the Bioconductor open source software (http://www.bioconductor.org/), followed by background correction with the function bgcorrect.illumina from the same R package. Detection P values were derived using the function detectionP as the probability of the total signal (methylation + unmethylated) being detected above the background signal level, as estimated from negative-control probes. Signals with detection P ≥ 0.01 were removed. Similarly, signals summarized from less than three functional beads on the chip were removed. Observations with less than 95% CpG sites providing a signal were subsequently excluded from the dataset. To reduce non-biological variability between observations, data were quantile normalized with the function normalizeQuantiles of the R package limma v.2.12.0 from Bioconductor, separately in six probe categories based on probe type and colour channel. If not stated otherwise, this preprocessing pipeline was used for all data used in downstream analyses.
In order to account for technical effects during the experiment, we performed principal component analysis on the signal intensities for the 235 positive control probes on the 450k array, which assess multiple steps in the laboratory processing. The resulting principal components are thought to capture technical variability in the experiment and the first 20 control-probe principal components were included as covariates in the model to remove technical biases.
To estimate proportions of white-blood-cell types, we used a previously described method 22 . They provide 500 CpG sites showing the most pronounced cell-type-specific methylation levels in an experiment based on purified cells. Of these, 473 CpGs were available on the 450k array. Following the proposed procedure and using the R code provided with the manuscript (R function projectWBC), we used these 473 CpG sites to infer white-blood-cell proportions (that is, the proportion of granulocytes, monocytes, B cells, CD4 + T cells, CD8 + T cells and natural killer cells) in our samples. These proportions were subsequently used as covariates in the model to avoid cell-type confounding. Epigenome-wide association. We performed single-marker tests separately in each cohort using linear regression to analyse the association of each autosomal CpG site with BMI; association results are presented, as the change in BMI per unit change in methylation (0-1 scale, corresponding to 0-100% change in methylation). We adjusted for age, gender, smoking status, physical activity index and alcohol consumption, as well as for the first 20 control-probe principal components and for the estimated white-blood-cell proportions; this set of covariates is henceforth referred to as 'discovery covariates' . We corrected the association results for the genomic control inflation factor (GC in ), in order to account for population stratification and other forms of cryptic structure in the data, which can arise for instance from unobserved confounding. Markers on the sex chromosomes were tested similarly for association with BMI, but separately in men and women. Results were combined across cohorts by inverse variance meta-analysis using METAL v.2011-03-25 (http://www.sph.umich.edu/csg/abecasis/Metal/). The resulting P values where then corrected for in a second round of genomic control (GC out ). There were 466,186 autosomal markers for analysis after quality control. We set the threshold for epigenome-wide significance as P < 1 × 10 −7 , to provide a conservative Bonferroni correction for the number of markers tested 23 . As additional analyses we also investigated the relationship between BMI and DNA methylation amongst the 11,233 X-chromosomal and 417 Y-chromosomal CpG sites assayed. Our sample size (n = 5,387 individuals) provides 80% power to identify a change of 8.4 kg m −2 in BMI per unit increase in methylation (that is, 0-1, in which 1 is 100% methylation) at P < 1.0 × 10 −7 .
To assess the stability of discovery results towards the analytic choices made, we performed sensitivity analyses to determine the impact of control-probe principal components, methylation principal components, and genetic principal components as covariates. Specifically, we compared results from the discovery meta-analysis when the first 10, 20, 30 and 40 control-probe principal components were included as covariates; 10 or 20 principal components derived from a principal component analysis on the matrix of methylation β values, 10 or 20 principal components derived from a principal component analysis on the matrix of methylation values adjusted for the discovery covariates and BMI, or 5 principal components derived from a principal component analysis on SNP data were included as covariates. Principal component analysis of the methylation data was performed separately for each cohort based on quantile normalized β values of autosomal probes without missing data. Genetic principal components (SNP principal components) were generated separately for each cohort and genotyping platform (Supplementary Table 25 ). The correlation between SNP principal components and methylation principal components was assessed using linear regression ( Supplementary Fig. 9 ). Discovery results are very stable towards the considered variations in covariates, with correlations of effect sizes between the models varying between 0.99-1.0 ( Supplementary Figs 3, 10 ). In addition, SNPs in the probe sequences did not materially affect the observed associations ( Supplementary Fig. 4 and Supplementary  Table 5 ). Replication testing. Markers associated with BMI at P < 1 × 10 −7 in the discovery experiment within ± 500 kb of each other were considered a single genetic region. At each locus we identified the CpG sites with lowest P value for association with BMI (sentinel marker). Our choice of 1 Mb to define a genetic locus was made to account for long-range enhancers.
At each locus we identified the sentinel marker, and carried out replication testing in separate samples of whole blood from European and Indian Asian men and women in population-based studies (n = 4,874, Supplementary Table 1 ). The 207 sentinel CpG sites were assayed using the Illumina 40K methylation array; cohort-specific details of analysis pipelines are described in Supplementary Table 2 . Results were combined across discovery and replication by weighted z metaanalysis. Epigenome-wide significance was set at P < 1 × 10 −7 providing Bonferroni correction for the 466,186 autosomal markers tested. Our choice of threshold is supported by the results of permutation testing 23 . 20 out of 207 markers did not reach P < 0.05 in replication testing. However, all 20 showed consistent direction of effect between discovery and replication stages (P = 1.9 × 10 −6 , binomial test; Supplementary Table 3 ), suggesting that the majority are unlikely to be false positive associations.
To assess whether the 187 sentinel CpGs were enriched for intermediately methylated CpGs (sites with 20-80% average methylation), we randomly generated 100,000 sets of 187 CpGs and determined the number of intermediately methylated CpGs for each of them in order to derive an expected distribution under the null hypothesis of no enrichment. We then compared the observed number of intermediately methylated CpGs for the 187 sentinel CpGs against the null distribution to calculate an empirical P value.
An exact binomial test (R function binom.test) was used to test whether a direction of effect between discovery and replication was observed more often than expected by chance amongst the 20 non-replicating CpG sites. Replication by pyrosequencing. As a technical validation, we used pyrosequencing to carry out replication testing of the relationship between DNA methylation and BMI at 4 loci, using samples of whole blood from 990 Europeans and 1,720 Indian Asians participating in the LOLIPOP study. Pyrosequencing was carried out using biotinylated primers to amplify bisulfite-treated DNA ( Supplementary Table 26 ). The biotinylated PCR products were then immobilized on streptavidin-coated Sepharose beads (GE Healthcare). Pyrosequencing was performed with the PyroMark Q96 MGMT kit (Qiagen) on a PSQTM96 MA system (Biotage). Samples for isolated white blood cell studies. 30 obese (BMI > 35 kg m −2 ) and 30 normal weight (BMI < 25 kg m −2 ) individuals were recruited at random from the outpatient departments at Ealing and University College London Hospitals. All participants gave written informed consent for inclusion in the study (research ethics committee references: 07/H0712/150, 13/LO/0477 and ID#09/H0715/65). Obese subjects and normal weight controls were matched by age (within 5 years), sex and ethnicity. Fluorescence activated cell sorting of white blood cells. For each participant, we collected 12 ml whole blood (EDTA). Samples were processed immediately to isolate white blood cell subsets (monocytes, neutrophils, CD4 and CD8 lymphocytes) through red blood cell lysis according to the manufacturer's instructions (BioLegend) and staining of unlysed white-blood-cell subsets (> 20 min in 50 μ l) Ca 2+ -free PBS with 5 mM EDTA and 1% human albumin; containing 1 μ l anti-CD14 PE-Cy7 (Clone-M5E2, BD), anti-CD16 BV510 (Clone-3G8, BioLegend), anti-CD45 BV605 (Clone-HI30, BioLegend), anti-CD8 APC (Clone-SK1, BioLegend); 2 μ l anti-CD3 PE (Clone-Leu-4, BD), anti-CD4 FITC (Clone-RPA-T4, BioLegend). Stained samples were filtered to remove clumped cells (30 μ m mesh, Miltenyi Biotec) and dead cells were stained (1 μ l Sytox Blue, Life Technologies) 24, 25 .
Lysed, stained samples were sorted on a FACSAria II SORP cell sorter at a flow rate of 6,000-9,000 events per second. Data was collected with FACSDiva 8 and analysed with FlowJo V10. Fluorescence minus one negative controls (that is, without the primary labelled antibody of interest) were used to determine positive and negative boundaries for each gate in the experimental set up. Daily Cytometer Set-up and Tracking quality control beads were run to ensure alignment and parameterization of the cell sorter (Anti-Mouse Igκ and Negative Control, BSA; Compensation Plus Particles, BD). Sytox Blue (450/50V nm) negative events were considered to be live cells. FCS-A and SSC-A were then used to separate granulocytes from monocyte and lymphocyte populations. Neutrophils (CD14 − , CD16 + ) were separated from other granulocytes. Monocytes were then separated from lymphocytes in a two-stage process as CD14 + , CD45 + and CD16 − cells. Finally, CD4 + and CD8 + cells were separated from other lymphocytes based on the following staining patterns; CD4 + cells: CD3 + , CD4 + , CD8 − , CD14 − and CD45 + ; and CD8 + cells: CD3 + , CD4 − , CD8 + , CD14 − and CD45 + . Sorted cell subsets were assessed for purity, then pelleted and snap-frozen for storage at − 80 °C. Average purities were: neutrophils 98.3% (± 1.2% (s.d.)); monocytes 99.2% (± 0.7%); CD4 + lymphocytes 99.6% (± 0.4%); CD8 + lymphocytes 97.9% (± 2.0%).
Genomic DNA was isolated (Qiagen QIAshredder; Allprep DNA/RNA Micro) according to manufacturer's instructions. Isolated genomic DNA was quantified (Qubit double-stranded DNA broad range assay) then stored at − 80 °C for genome-wide DNA-methylation assays. Quantification of DNA methylation and data processing. Genomic DNA (0.2-1.0 μ g) was bisulfite converted using an EZ DNA Methylation-Direct Kit (Zymo Research). In brief, DNA samples were bisulfite converted by incubation with the CT conversion reagent for 8 min at 98 °C, 3.5 h at 64 °C, followed by 18 h at 4 °C in a thermocycler. The treated DNA was added to a Zymo-Spin IC Column, desulfonated using M-desulphonation buffer, and then eluted from the column in 12 μ l of M-elution buffer.
Methylation analysis of the bisulfite-treated DNA was performed using an Illumina Infinium MethylationEPIC Beadchip (Illumina) according to the standard protocol. In brief, 4 μ l of bisulfite-treated DNA was denatured, neutralized and amplified with an overnight whole-genome amplification reaction. The amplified DNA was then enzymatically fragmented, precipitated and resuspended in hybridi zation buffer before being dispensed onto the MethylationEPIC beadchips for hybridization. After hybridization, the beadchips were processed through a primer-extension protocol and subsequently stained. Finally, the beadchips were coated and imaged using the HiScan System (Illumina).
All samples passed quality control and principal component analysis showed clear separation of cell-types. Methylation values for 179 (out of 187) sentinel CpGs were retrieved, as described above for epigenome-wide association in blood, and the difference in DNA methylation between obese cases and normal weight controls was tested using linear regression, adjusted for age, gender and ethnicity. Genetic association studies. We used genetic association and the concept of Mendelian randomization to investigate for potential causal relationships between DNA methylation and adiposity 11 . In brief, Mendelian randomization goes back to the more general instrumental variable concept. As an instrumental variable, it uses a genetic variant (or a combination of genetic variants) Z associated with a variable X in order to show a causal relation between X and another variable Y. It relies on the fact that the alleles of a genetic variant are inherited randomly from parents to offspring, so that the relation of a genetic variant with a phenotype should not be confounded (with exceptions including population stratification). Thus, if the effect of X on Y is causal and the study has enough power, Z should also associate with Y. Specifically, the predicted association of Z with Y can be calculated as follows, assuming linear relationships and assuming that Z is unrelated to Y given X and unrelated to any unobserved confounders U (where α is the intercept, and β and γ are the beta-coefficients for the relationships of X with Z and U, respectively): Therefore the predicted effect of Z on Y is β 3 = β 2 β 1 Unbiased estimation and formal inference on the causal effect β 1 of X on Y (where X and Y represent a CpG-phenotype pair) relies on strong genetic effects and typically requires tens of thousands of samples for adequate power 26 . As these sample sizes are currently not available for epigenomic datasets, we explored the consistency of the predicted effect of Z on Y compared to the observed effect instead, thereby obtaining some indication on the plausibility of a causal effect of X on Y. This was done in two directions, studying causality of the effect of DNA methylation (X) on BMI (Y) and of BMI (X) on DNA methylation (Y).
DNA methylation as determinant of BMI (causal analysis).
To investigate whether DNA methylation is a determinant of BMI (whereby X = DNA methylation, Y = BMI) we used data on genetic variants from 4,034 participants of the KORA and LOLIPOP studies ( Supplementary Table 25 ) to identify cis (1 Mb) SNPs (Z) influencing methylation in blood at the 187 sentinel CpG sites. The associations between SNPs and methylation were tested in each dataset separately using linear models with methylation as response and SNP as independent variable, adjusting for the discovery covariates, and then combined by inverse variance meta-analysis using METAL v.2011-03-25. Our sample size (n max = 4,034 individuals) provides 80% power to identify a change in methylation of 0.5% (in absolute terms) per allele copy at P < 5.0 × 10 −8 (that is, genome-wide significance). Results for all 173,367 pairs reaching P < 5 × 10 −8 (conventional genomewide significance) are provided in Supplementary Table 27 . We excluded 3 CpGs that shared no cis SNPs across all datasets, and a further 9 CpGs because they had SNPs within their probe-binding sequence. For the remaining 175 CpG sites, the single SNP with the lowest P value for association with methylation was chosen as an instrumental variable (Supplementary Table 28 ). As mentioned above, to be an appropriate instrument, a SNP must not be directly associated with BMI (Y), only through the respective CpG (X). For this purpose, we removed six CpG-SNP pairs from the analysis because the corresponding SNPs remained associated with BMI after adjustment for the sentinel CpG (cg07136133, cg08548559, cg09152259, cg12484113, cg18120259 and cg26403843). Statistical significance was inferred at P < 2.9 × 10 −4 (corresponding to P < 0.05 after Bonferroni correction for 175 tests).
To enable comparison with the observed effect of SNPs on BMI obtained from published data, we assessed the relationship between DNA methylation and adiposity in linear models, using an inverse-normal transformation of BMI as the outcome variable to be consistent with the GIANT genome-wide association study (GWAS) 12 . The associations between DNA methylation and inverse-normal transformed BMI were quantified in LOLIPOP and KORA cohorts separately, followed by inverse variance meta-analysis using METAL v.2011-03-25. We then calculated the predicted effect sizes and standard errors (β pred and SE pred , respectively) as follows (where the term A~ B refers to the magnitude of the relationship between A and B in regression analysis): The predicted effect sizes were compared to the observed effects of SNPs on BMI, whereby the latter were obtained from a large published GWAS to increase power 12 .
Statistical significance for individual SNPs was inferred at P < 2.9 × 10 −4 . We used correlation analysis to investigate the global relationship between predicted and observed effects on BMI for the SNPs influencing DNA methylation across the sentinel CpG sites.
DNA methylation as consequence of BMI (consequential analysis).
To test the hypothesis of DNA methylation being a consequence of BMI (whereby X = BMI, Y = DNA methylation), we followed a similar procedure as described above for the opposite direction with minor differences. First, instead of using a single SNP as instrumental variable, we calculated a weighted genetic risk score (GRS) comprising SNPs reported to influence BMI 12 . Again, for the GRS to provide a valid instrument, the included SNPs must not show direct association with the CpG (Y) but only through BMI (X). For this purpose we removed three SNPs (rs12444979, rs10968576 and rs7359397) which remained significantly associated at P < 8.4 × 10 −6 (corresponding to P < 0.05 after Bonferroni correction for the 187 × 32 tests performed) with at least one of the sentinel CpGs after adjusting for BMI. The final GRS was calculated as the sum of risk allele dosage of the remaining 29 SNPs previously reported to associate with BMI, weighted by the reported effect sizes 12 .
Second, the observed effects of GRS on DNA methylation were quantified using linear models as described above adjusted for the discovery covariates amongst participants of the KORA and LOLIPOP studies. Regression analysis was carried out in the KORA and LOLIPOP cohorts separately and results combined by inverse variance meta-analysis using METAL v.2011-03-25. DNA methylation in blood and adiposity in prospective population studies. We used data from the KORA (n = 1,435 Europeans) and LOLIPOP (n = 1513 Indian Asians) studies to examine the prospective, longitudinal association between DNA methylation at baseline and subsequent change in BMI during follow-up. We carried out linear regression with change in BMI during follow-up as response variable, and technically adjusted baseline methylation as the predictor variable, with age, sex, physical activity, smoking, alcohol intake, estimated white-blood-cell proportions and BMI at baseline, as well as follow-up time as additional covariates. Data were analysed in KORA and LOLIPOP separately, followed by inverse variance meta-analysis using METAL v.2011-03-25.
We studied the longitudinal relationship between change in BMI and change in DNA methylation amongst 1,435 participants of the KORA S4/F4 cohort with methylation data available both at baseline and at the 7-year follow-up time point. To ensure comparability of methylation measurements from the two time points measured in two batches, methylation β-values were jointly adjusted for the first 20 principal components obtained from a principal component analysis on the positive-control probes, and residuals were subsequently used as adjusted methylation values. Linear models were used with change in BMI during follow-up as response variable, and change in technically adjusted methylation as independent variable, including age, sex, physical activity, smoking, alcohol intake and estimated white-blood-cell proportions both at baseline and follow-up. DNA methylation in adipose tissue. We investigated whether the observed methylation markers in blood are representative of BMI-associated methylation changes in adipose tissue. We used a dataset of 542 adipose tissue samples from the TwinsUK study to test association of the 187 identified methylation markers with BMI. The association of BMI with methylation was quantified using a linear mixed-effects model adjusting for chip, for bisulfite conversion level and bisulfite conversion efficiency, smoking state (3 categories: current, former and never smokers), alcohol intake (in g per day) and age, with zygosity and family as random effects.
We carried out sensitivity analyses to assess the potential contribution of cryptic structure arising from differences in cell composition of the adipose tissue samples. In the absence of validated approaches for imputation and adjustment for adipose-tissue cell-subset composition, and the potential limitations of published reference-free approaches for separation of true and confounded signals 23 , we used principal component analysis to quantify latent structure in the adipose-tissue methylation data, and included the top 5 components as covariates in the regression model.
We separately compared DNA methylation between paired samples of blood and subcutaneous adipose tissue (available for the same n = 201 individuals, TwinsUK). Blood methylation values were first adjusted for age, chip and chip position, smoking state, alcohol intake, and estimated white-blood-cell subsets by taking the residuals from a linear model with these as covariates. Similarly, adipose tissue methylation values were adjusted for age, chip, bisulfite conversion level, bisulfite conversion efficiency, smoking state, alcohol intake and the top 5 principal components from the adipose methylation data. Pearson's correlation was then determined between the adjusted methylation values.
Finally, we used genetic association to carry out causality analyses on the association between BMI and DNA methylation in adipose tissue, as described above for blood. We studied a subset of 325 adipose tissue samples from the TwinsUK cohort with genotype data available. Regression analyses in adipose tissue between BMI, SNPs/genetic risk score and CpGs were carried out using the R package lme4, and with smoking, alcohol intake, age, zygosity (random effect), family (random-effect), beadchip, bisulfite conversion batch and bisulfite conversion efficiency as covariates. DNA methylation in isolated adipocytes. Subcutaneous adipose tissue samples were obtained intraoperatively in 24 morbidly obese individuals (BMI > 40 kg m −2 ) undergoing laparoscopic bariatric surgery and 24 healthy controls (BMI < 30 kg m −2 ) undergoing non-bariatric laparoscopic abdominal surgery. Participants were unrelated, between 18-60 years of age, from a multiethnic background, and free from type 2 diabetes. Controls were matched to cases by age, sex and ethnicity. All participants gave informed consent (Ethics committee reference 13/LO/0477).
Adipose samples were processed immediately to isolate populations of primary human adipocyte cells using established protocols 27 . Polypropylene plastic ware was used to minimise adipocyte cell lysis. Adipose tissue samples were minced into 1-2 mm 3 pieces and washed in Hank's buffered salt solution (HBSS), before digestion using type 1 collagenase (1 mg ml −1 , Worthington) in a water bath at 37 °C shaking at 100 r.p.m. for approximately 45 min. Digested samples were filtered through a 300-μ m nylon mesh to remove debris, and the filtered solution centrifuged at low speed (500g; 5 min; 4 °C), to leave four layers, from top to bottom: (1) oil, (2) mature adipocytes, (3) supernatant and (4) stromovascular pellet. After removal of the oil layer, the mature adipocyte layer was collected by pipette, washed in approximately 5× volume of HBSS and recentrifuged. After 3 washes the adipocyte cell suspension was collected for snap-freezing and storage at − 80C.
Genomic DNA and RNA were extracted from the isolated adipocytes using the Qiagen AllPrep DNA/RNA/miRNA Universal Kit according to manufacturer's protocol for lipid-rich samples. Methylation of genomic DNA was quantified using the Illumina HumanMethylation450 array in a single batch according to manufacturer's specifications. Raw methylation data were preprocessed using R v.2.15. Bead intensity was retrieved using the R package minfi v.1.6.0. Marker intensities were quantile normalized for analysis. Principal component analysis of control probe intensities was performed to quantify cryptic structure in the data arising from technical factors. Logistic regression was used to examine the association of each CpG site with morbid obesity compared to normal weight, adjusting for age, sex and ethnicity, and the first five control probe principal components. DNA methylation in liver tissue. Liver samples were obtained percutaneously for patients undergoing liver biopsy for suspected NAFLD or intraoperatively for assessment of liver histology. Normal control samples were recruited from samples obtained for exclusion of liver malignancy during major oncological surgery. None of the normal control individuals underwent pre-operative chemotherapy and liver histology demonstrated absence of both cirrhosis and malignancy. Study design, sampling method and data collection have been described in detail elsewhere 28 . For methylation analysis, bisulfite conversion was performed using the Zymo EZ DNA Methylation Kit (Zymo Research), and hybridization of the Illumina HumanMethylation450 array (Illumina). mRNA expression analysis was performed using the HuGene 1.1 ST gene (Affymetrix) according to the manufacturers' protocols. Hybridization signals were analysed using GenomeStudio software (default settings; GenomeStudio v.2011.1, Methylation Analysis Module v.1.9.0; Illumina Inc) and internal controls for normalization. Cross-tissue methylation. For extended cross-tissue correlation analyses, publicly available data (GSE48472) were downloaded from the Gene Expression Omnibus (GEO) database 9 . Briefly, the dataset consists of 41 samples from six individuals of blood, liver, muscle, pancreas, subcutaneous fat, omentum and spleen analysed on the 450k methylation array. Data from the 187 CpG sites of interest were extracted and plotted using the heatmap.2 function in the R package gplots (v.2.17.0). Mean methylation levels for each CpG site across all samples within each tissue type were used to test for pairwise correlation between tissue types. Genomic annotation analyses. To test for functional enrichment of the 187 CpG sites associated with BMI, we used annotations of genomic context provided by Illumina, and of histone modification ChIP peaks (H3K4me1, H3K4me3 and H3K27Ac, marks of open chromatin) and DNaseI Hypersensitivity Sites in 127 different cell types in the Roadmap and ENCODE (Release 9, UCSC) datasets. We mapped each probe on the Illumina 450k array background to the annotation categories and recorded overlap at each probe as a binary variable. To determine whether enrichment occurred more often than expected by chance, we generated 10,000 sets of 187 CpGs, each matched with the BMI sentinel CpGs for methylation mean (± 2%) and standard deviation (± 0.2%), but otherwise selected at random. For each epigenetic mark, we then calculated the number of overlapping sites amongst the 187 replicating markers (observed) and 10,000 permuted sets of 187 markers (expected). We calculated the fold enrichment as observed/mean (expected) and obtained an empirical P value from the distribution of expected. Gene expression studies. Transcriptome-wide measurements of gene expression in blood along with measurements of DNA methylation from the same blood sample were available for participants of both the KORA F4 (n = 703) and LOLIPOP (n = 1,082, 907 Indian Asians, 175 Europeans) studies ( Supplementary  Table 15 ). KORA samples were analysed with the Illumina HumanHT-12 v3 BeadChip array. Blood sample collection and RNA isolation and preparation have been described in detail 29, 30 . Gene expression data were quantile normalized and log 2 transformed using the R package lumi, v.2.8.0, from Bioconductor in R, v.2.14.2. In LOLIPOP, gene expression analysis was performed with the Illumina HumanHT-12 v4 BeadChip array according to manufacturer's protocol. Background correction (using negative controls), quantile normalization and log 2 transformation was performed using the R package limma (function neqc).
To examine associations of DNA methylation with gene expression we carried out linear regression with log 2 transformed gene expression as the response variable and methylation β values as independent variable. In KORA, the model was adjusted for the discovery covariates and technical covariates related to the expression measurement (RNA integrity number, RNA amplification plate, sample storage time). In LOLIPOP, the model was adjusted for age, sex, methylation control probe principal components and technical covariates related to the expression measurement (RNA integrity number, RNA extraction batch, RNA conversion batch, scanning batch, array and array position). Results were analysed in KORA, LOLIPOP Indian Asians and LOLIPOP Europeans separately, then combined by inverse-variance meta-analysis using METAL v.2011-03.25. Statistical significance was inferred at P < 9.0 × 10 −6 (that is, P < 0.05 after Bonferroni correction for 5,551 CpG-expression pairs).
To assess whether the 187 sentinel CpGs were enriched for association with gene expression, we used the same testing concept as described above based on Letter reSeArCH constructing a null distribution from 10,000 randomly selected, matched sets of 187 CpGs. For each permuted set we determined the number of significantly associated expression probes in cis (P < 9.0 × 10 −6 ) as described above and compare the resulting distribution with the observed number of gene expression associations for the 187 sentinel CpG sites to calculate an empirical P value.
Finally, we examined the association between DNA methylation and gene expression in TwinsUK adipose tissue samples (n = 499) for the 44 methylationexpression pairs that were significant in blood. Expression values were adjusted for age and chip using a linear model. The association of methylation and expression was then determined in linear mixed-effects models with adjusted expression as response and methylation as the independent variable, adjusting for age, chip, bisulfite conversion level and bisulfite conversion efficiency, with zygosity and family as random effects. After QC filtering of methylation and expression data, results were available for 36 methylation-expression pairs. Candidate genes and gene-set-enrichment analyses. The standard Illumina annotation does not identify genes for all CpG sites on the 450K microarray. We therefore identified candidate genes based on the following criteria: (1) proximity, gene nearest to the CpG site (n = 187 genes), and (2) gene expression, all local genes (up to ± 500 kb) with expression associated with the marker at P < 0.05 after Bonferroni correction for 5,551 tests (n = 38 genes). This resulted in a list of 210 unique genes ( Supplementary Table 19 ).
Gene annotations were downloaded from Ensembl (https://grch37.ensembl. org/index.html) using the R package biomaRt v.2.18.0 from Bioconductor, and overlapped with the cg positions as annotated in the Illumina annotation using the R package GenomicRanges v.1.14.4 from Bioconductor. We downloaded curated pathway information (c2.all.v5.0.symbols.gmt) from the GSEA MSigDB platform (http://www.broadinstitute.org/gsea/msigdb), resulting in 1,135 pathways, to investigate enrichment of the set of candidate genes against curated pathway sets (BIOCARTA, KEGG, REACTOME). An enrichment P value was calculated empirically on the basis of permutation testing, using the Benjamini-Hochberg (false-discovery rate) procedure. For the sensitivity analysis, the gene-setenrichment analysis was repeated using the genes annotated by Illumina, and using more permissive proximity criteria ( Supplementary Table 29 ). Results become less statistically significant when candidate gene selection based on proximity alone was extended to include all genes over distances up to 500 kb. DNA methylation and metabolic traits. We investigated the association between the 187 sentinel methylation markers and metabolic disturbances associated with adiposity amongst participants of the KORA (n = 1,697) and LOLIPOP (n = 2,462) studies with available measurements of the following BMI-related clinical traits: LDL (low-density lipoprotein) cholesterol, HDL cholesterol, total cholesterol, fasting triglycerides, fasting glucose, fasting insulin, HbA1c, systolic and diastolic blood pressure, C-reactive protein, weight, height and waist-hip ratio. Linear models were used with trait as response and methylation as independent variable, adjusting for the discovery covariates. Results from KORA and LOLIPOP studies were analysed separately, then combined by inverse variance meta-analysis using METAL v.2011-03-25. Associations were considered significant at P < 2.1 × 10 −5 (corresponding to P < 0.05 after Bonferroni correction for 187 × 13 tests).
To investigate potential causal relationships between the methylation markers and BMI-related clinical traits, we performed causality analyses as described above for the primary phenotype (BMI). For each clinical trait, GWAS datasets of the most comprehensive meta-analyses published to date with access to genome-wide association results were retrieved ( Supplementary Table 30 ), to provide SNPs influencing trait. SNPs associated with multiple traits were assigned to the most strongly associated trait (lowest P value). Clinical traits were transformed as described in the respective GWAS. Genetic risk scores were calculated as described above for BMI, after removal of SNPs with direct genomic effects (SNPs that remain associated with the sentinel CpG after adjustment for the trait). Regression analyses were carried out in the KORA F4 and LOLIPOP cohorts separately and results were combined by inverse variance meta-analysis using METAL v.2011-03-25. Association with incident type 2 diabetes. We tested the association of DNA methylation at the 187 identified CpG sites with incident type 2 diabetes amongst participants of the LOLIPOP study. All participants (n = 2,664) were free from type 2 diabetes at the time of measurement of DNA methylation; incident type 2 diabetes (n = 1,074) was defined as either new physician diagnosis, or HbA1c ≥ 6.5%. Associations with type 2 diabetes were evaluated by logistic regression adjusted for the discovery covariates. We initially tested the association in single-marker tests, then in a fully saturated model comprising all 187 markers to identify independent effects.
To combine information across loci, we calculated a weighted methylation risk score as the sum of the standardised methylation values at each marker that reached nominal significance (P < 0.05) in the fully saturated multivariate model, weighted by marker-specific effect size. We then tested the association of the methylation risk score with incident type 2 diabetes using logistic regression, before and after adjustment for traditional type 2 diabetes risk factors (BMI, waist-hip ratio, glucose and HbA1c).
Replication testing of the association of methylation risk score with type 2 diabetes was carried out in a nested case-control study within the KORA S3/S4 comprising 200 subjects with newly diagnosed type 2 diabetes and 200 controls matched for age (± 2 years), sex, cohort and observation time until diagnosis of diabetes. Data were analysed using conditional logistic regression using the function clogit of the R package survival v.2.37.4. Software. Unless stated otherwise, all calculations were performed using R v.3.0.1. For all meta-analyses, METAL v.2011-03-25 was used. Custom R code for the respective analyses is available at: http://metabolomics.helmholtz-muenchen.de/ bmi_methylation/. Data availability. Summary statistics from the epigenome-wide association study can be accessed from the European Genome-phenome Archive (EGAS00001001922; https://www.ebi.ac.uk/ega/studies/EGAS00001001922). KORA methylation data are available upon request through the application tool KORA.PASST (http:/epi.helmholtz-muenchen.de); LOLIPOP data are available from the Gene Expression Omnibus (GSE55763); EPICOR data are deposited in the HuGeF repository (http://www.hugef-torino.org) and are available on request.
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Extended Data Figure 1 | Study design. Epigenome-wide association and replication testing was performed in order to identify methylation sites associated with adiposity. In the discovery step, four large cohorts were included with Illumina 450k DNA methylation data available, which were preprocessed and quality controlled according to a harmonized protocol. Epigenome-wide association was performed in every single study with BMI as response variable and methylation β -value as independent variable, adjusting for covariates as described in the Methods. At a genome-wide significance level of P < 1 × 10 −7 , 278 methylation sites from 207 regions were identified. In the replication step, 187 of these were replicated in independent samples. Genetic association and causality analyses were used in order to investigate whether the identified methylation signals underlie the development of adiposity or are the consequence of adiposity. The findings were supported by longitudinal analyses. The cross-tissue analyses represent a first step towards extending our observations in blood to metabolically relevant tissues. The functional genomics and gene expression analyses help to link the observed methylation associations to transcriptional outcomes, while the gene-set enrichment analysis provides a way to summarize the potentially affected metabolic pathways. Finally, we studied the relationships between methylation and adiposity-related metabolic traits and type 2 diabetes to address the clinical relevance of our findings.
Extended Data Figure 10 | Association of established and emergent biomarkers with type 2 diabetes. Results are presented as risk of type 2 diabetes associated with the specified biomarkers in three models: model 1, adjusted for age and sex; model 2, as for model 1, but additionally adjusted for body mass index and impaired fasting glucose; and model 3, as for model 2, but additionally adjusted for central obesity and insulin concentrations. CRP, C-reactive protein; MRS, methylation risk score. Results for quantitative traits (amino acids, C-reactive protein, insulin and methylation risk score) are presented as risk of type 2 diabetes in Q4 compared to Q1.
